<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398225</url>
  </required_header>
  <id_info>
    <org_study_id>405-201-00010</org_study_id>
    <nct_id>NCT04398225</nct_id>
  </id_info>
  <brief_title>A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder</brief_title>
  <official_title>A Phase 1b, Multicenter, Open-label, Multiple Ascending Dose Trial to Assess the Pharmacokinetics, Safety and Tolerability of Centanafadine Extended-release Capsules After Oral Administration in Pediatric Subjects (4 to 12 Years, Inclusive) With Attention-deficit/Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate the pharmacokinetics, safety, and tolerability of centanafadine in
      pediatric subjects with ADHD.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal peak plasma concentration (Cmax)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time 0 to 24 hours (AUC0-24h) on day 14</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance and apparent volume of distribution of centanafadine on Day 14</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (9-12 y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (9-12 y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Centanafadine extended release capsule; 200 mg adult equivalent; twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (9-12 y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Centanafadine extended release capsule; 400 mg adult equivalent; twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 (4-8 y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 (4-8 y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Centanafadine extended release capsule; 200 mg adult equivalent; twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 (4-8 y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Centanafadine extended release capsule; 400 mg adult equivalent; twice daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Centanafadine</intervention_name>
    <description>Extended release capsule</description>
    <arm_group_label>Cohort 1 (9-12 y)</arm_group_label>
    <arm_group_label>Cohort 2 (9-12 y)</arm_group_label>
    <arm_group_label>Cohort 3 (9-12 y)</arm_group_label>
    <arm_group_label>Cohort 4 (4-8 y)</arm_group_label>
    <arm_group_label>Cohort 5 (4-8 y)</arm_group_label>
    <arm_group_label>Cohort 6 (4-8 y)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects 4 to 12 years of age, inclusive, at the time of informed
             consent/assent.

          -  Subjects must weight â‰¥ 13 kg.

          -  Subjects with a diagnosis of any ADHD subtype based on Diagnostic and Statistical
             Manual of Mental Disorders, 5th edition (DSM-5) criteria and confirmed by the
             Mini-International Neuropsychiatric Interview for Children and Adolescents (MINI-Kid).

          -  Subject is judged by the investigator to be clinically stable, and has not had any
             psychiatric hospitalizations within the past 12 weeks.

          -  Subjects and their caregivers must be able and willing to utilize the AiCure Platform
             for each daily dose.

        Exclusion Criteria:

          -  Subjects with a clinical presentation or history that is consistent with delirium,
             dementia, amnesia, or other cognitive disorders; subjects with psychiatric symptoms
             that are better accounted for by another psychiatric or general medical condition(s)
             or direct effect of a substance.

          -  Subjects with developmental disorders, such as Autism Spectrum Disorder.

          -  Subjects with a history of at least mild intellectual disability as determined by IQ &lt;
             70, clinical evidence, or a social or school history that is suggestive of
             intellectual disability.

          -  Subjects with hypothyroidism or hyperthyroidism (unless condition has been stabilized
             with medications for at least 90 days prior to first dose of IMP) or an abnormal
             result for free T4 at screening.

          -  Subjects who currently have clinically significant neurological, dermatological,
             hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, or
             gastrointestinal disorders such as any history of myocardial infarction, congestive
             heart failure, HIV seropositive status/AIDS, or chronic hepatitis B or C.

          -  Subjects with insulin dependent diabetes mellitus (i.e. any subjects using insulin)

          -  Subjects with epilepsy, Tourette's Disorder, or a history of seizures or a history of
             severe head trauma or cerebrovascular disease.

          -  Any major surgery within 30 days prior to the first dose of IMP.

          -  Any history of significant bleeding or hemorrhagic tendencies.

          -  Blood transfusions within 30 days prior to the first dose of IMP.

          -  Subjects who have supine or standing diastolic blood pressure, after resting for at
             least 5 minutes, &gt; 80 mmHg.

          -  Subjects who participated in a clinical trial and were exposed to IMP within the last
             30 days prior to screening or who participated in more than 2 interventional clinical
             trials within the past year. Subjects who have had any previous exposure to
             centanafadine.

          -  Subjects with a history of true allergic response to a medication or a history of
             dermatologic adverse reactions or anaphylaxis secondary drug exposure.

          -  Subjects with a history of allergic reaction or known or suspected sensitivity to any
             substance that is contained in the IMP formulation.

          -  Subjects who do not tolerate venipuncture or have poor venous access that would cause
             difficulty for collecting blood samples.

          -  Consumption of alcohol and/or food and beverages containing methylxanthines, foods
             known to affect CYP1A2 (e.g. charbroiled or pan-fried meats and cruciferous
             vegetables) within 72 hours prior to dosing.

          -  Relative of the trial site employees cannot participate in the trial.

          -  Siblings, other family members, and those having the same place of residence as the
             subject are also excluded from the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Otsuka Call Center</last_name>
    <phone>844-687-8522</phone>
    <email>OtsukaRMReconciliation@rmpdc.org</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

